Nivolumab in renal cell carcinoma

Ortega Rosa M. Michel; Drabkin Harry A.

首页> 外文期刊>Expert opinion on biological therapy >Nivolumab in renal cell carcinoma

【24h】

Nivolumab in renal cell carcinoma

机译：尼武单抗治疗肾细胞癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Immune-based therapies (e.g., IFN) have been used for some time in advanced clear cell renal cell carcinoma (RCC) with overall modest success. Recent advances have demonstrated that tumor cells evade immune-mediated destruction by inducing inhibitory signals that result in effector T-cell exhaustion. One mechanism involves interaction between the T-cell programmed death-1 (PD-1) receptor and its ligand, PD ligand-1, expressed on tumor and inflammatory cells. Nivolumab, an anti-PD-1 antibody, blocks this pathway, thereby reversing T-cell suppression and activating antitumor responses.

机译：简介：免疫疗法（例如IFN）已在晚期透明细胞肾细胞癌（RCC）中使用了一段时间，总体上取得了一定的成功。最近的进展表明，肿瘤细胞通过诱导抑制性信号而逃避免疫介导的破坏，所述抑制性信号导致效应器T细胞衰竭。一种机制涉及在肿瘤和炎性细胞上表达的T细胞程序性死亡1（PD-1）受体与其配体PD配体1之间的相互作用。抗PD-1抗体Nivolumab阻断了该途径，从而逆转了T细胞抑制作用并激活了抗肿瘤反应。

著录项

来源
《Expert opinion on biological therapy》 |2015年第7期|共12页
作者
Ortega Rosa M. Michel; Drabkin Harry A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词
anti-programmed death-1; immune checkpoint; immunotherapy; nivolumab; renal cell carcinoma; targeted therapy;

机译：抗程序性死亡1;免疫检查点;免疫治疗;尼古卢单抗;肾细胞癌;靶向治疗;

相似文献

外文文献
中文文献
专利

1. Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma [J] . Chedgy Edmund C. P., Black Peter C. Urology . 2016,第Null期

机译：Nivolumab：新的第二线治疗晚期肾 - 细胞癌评论：Nivolumab与Everolimus在晚期肾细胞癌中
2. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab? [J] . Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2020,第4期

机译：耐久的反应后患有转移性肾细胞癌中的Nivolumab：肾毒性是预测Nivolumab的益处的标记吗？
3. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium [J] . I. Stukalin, J. C. Wells, J. Graham, Current oncology . 2019,第2期

机译：尼伏鲁单抗和卡博替尼在转移性肾细胞癌中的真实结果：国际转移性肾细胞癌数据库联合会的结果
4. Application of High-Throughput Sequencing Data Mining in Comparison of Gene Expression Profile in Renal Cell Carcinoma and Normal Renal Cell by RNA-Seq [C] . Yunhai Yu, Hongmei Xu, Shaoning Guo, International Conference on Innovative Computing . 2020

机译：高通量测序数据挖掘在RNA-SEQ肾细胞癌和正常肾细胞中基因表达谱的比较中的应用
5. Integrated Molecular Analysis for the Identification and Validation of Novel Biomarkers for Renal Cell Carcinoma and the Small Renal Mass [D] . Di Meo, Ashley . 2019

机译：肾细胞癌新生物标志物的鉴定和验证综合分子分析及小肾肿块
6. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium [O] . I. Stukalin, J.C. Wells, J. Graham, 2019

机译：尼伏鲁单抗和卡博替尼在转移性肾细胞癌中的真实结果：国际转移性肾细胞癌数据库联合会的结果
7. Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium [O] . I. Stukalin, J.C. Wells, J. Graham, 2019

机译：Nivolumab和Cabozantib在转移性肾细胞癌中的现实世界结果：国际转移性肾细胞癌数据库联盟的结果

Nivolumab in renal cell carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅